XML 28 R14.htm IDEA: XBRL DOCUMENT
v3.19.3

Earnings per Share | 9 Months Ended
--- | ---
Nov. 02, 2019
Earnings Per Share [Abstract] |
Earnings per Share | 7. Earnings per Share The following table provides a reconciliation of the number of shares outstanding for basic and diluted earnings per share:
|  | For the three months ended |  |  | For the nine months ended |
|  | November 2, 2019 |  |  | November 3, 2018 |  |  | November 2, 2019 |  |  | November 3, 2018 |
(in thousands) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic weighted average common shares outstanding |  |  | 50,089 |  |  |  | 49,352 |  |  |  | 49,853 |  |  |  | 49,068 |
Common stock equivalents – stock options and restricted stock (1) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Diluted weighted average common shares outstanding |  |  | 50,089 |  |  |  | 49,352 |  |  |  | 49,853 |  |  |  | 49,068 |
| (1) | Common stock equivalents of 324 shares and 581 shares for the three months ended November 2, 2019 and November 3, 2018, respectively, and 404 shares and 494 shares for the first nine months ended November 2, 2019 and November 3, 2018, respectively, were excluded due to the net loss in each period.
The following potential common stock equivalents were excluded from the computation of diluted earnings per share in each period, because the exercise price of such options was greater than the average market price per share of common stock for the respective periods or because of the unearned compensation associated with either stock options, restricted stock units, restricted or deferred stock had an anti-dilutive effect.
|  | For the three months ended |  |  | For the nine months ended |
|  | November 2, 2019 |  |  | November 3, 2018 |  |  | November 2, 2019 |  |  | November 3, 2018 |
(in thousands, except exercise prices) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock options |  |  | 819 |  |  |  | 963 |  |  |  | 804 |  |  |  | 963 |
Restricted stock units |  |  | 1,242 |  |  |  | 754 |  |  |  | 679 |  |  |  | 786 |
Restricted and deferred stock |  |  | 114 |  |  |  | 24 |  |  |  | 114 |  |  |  | 57 |
Range of exercise prices of such options |  | $1.85 - $7.02 |  |  | $2.25 - $7.02 |  |  | $2.25- $7.02 |  |  | $2.25 - $7.02 |
The above options, which were outstanding at November 2, 2019, expire from March 19, 2020 to June 29, 2028. Shares of unvested restricted stock of 30,000 shares at November 3, 2018 were excluded from the computation of basic earnings per share. There were no unvested shares of restricted stock outstanding at November 2, 2019. The 720,000 PSUs are excluded from basic and diluted earnings per share until the market condition is achieved.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration